CoChat
Sign Up
Cited by 185Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease

Open access
Öhrfelt, Annika, Brinkmalm, Ann, Dumurgier, Julien, Brinkmalm, Gunnar, Hansson, Oskar, Zetterberg, Henrik, Bouaziz-Amar, Elodie, Hugon, Jacques, Paquet, Claire, Blennow, Kaj·2016·Alzheimer's Research & Therapy
DOI 10.1186/s13195-016-0208-8PMC PMC5048479
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Synaptic degeneration is a central pathogenic event in Alzheimer's disease that occurs early during the course of disease and correlates with cognitive symptoms. The pre-synaptic vesicle protein synaptotagmin-1 appears to be essential for the maintenance of an intact synaptic transmission and cognitive function. Synaptotagmin-1 in cerebrospinal fluid is a candidate Alzheimer biomarker for synaptic dysfunction that also may correlate with cognitive decline. METHODS: In this study, a novel mass spectrometry-based assay for measurement of cerebrospinal fluid synaptotagmin-1 was developed, and was evaluated in two independent sample sets of patients and controls. Sample set I included cerebrospinal fluid samples from patients with dementia due to Alzheimer's disease (N = 17, age 52-86 years), patients with mild cognitive impairment due to Alzheimer's disease (N = 5, age 62-88 years), and controls (N = 17, age 41-82 years). Sample set II included cerebrospinal fluid samples from patients with dementia due to Alzheimer's disease (N = 24, age 52-84 years), patients with mild cognitive impairment due to Alzheimer's disease (N = 18, age 58-83 years), and controls (N = 36, age 43-80 years). RESULTS: The reproducibility of the novel method showed coefficients of variation of the measured synaptotagmin-1 peptide 215-223 (VPYSELGGK) and peptide 238-245 (HDIIGEFK) of 14 % or below. In both investigated sample sets, the CSF levels of synaptotagmin-1 were significantly increased in patients with dementia due to Alzheimer's disease (P ≤ 0.0001) and in patients with mild cognitive impairment due to Alzheimer's disease (P < 0.001). In addition, in sample set I the synaptotagmin-1 level was significantly higher in patients with mild cognitive impairment due to Alzheimer's disease compared with patients with dementia due to Alzheimer's disease (P ≤ 0.05). CONCLUSIONS: Cerebrospinal fluid synaptotagmin-1 is a promising biomarker to monitor synaptic dysfunction and degeneration in Alzheimer's disease that may be useful for clinical diagnosis, to monitor effect on synaptic integrity by novel drug candidates, and to explore pathophysiology directly in patients with Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-016-0208-8

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Targeted HR-PRM-MS analyses of synaptotagmin in human CSF. Individual values for the HR-PRM-MS measured peak area ratios ((endogenous peptide/labeled peptide standard) × 1000) of immunoprecipitated synaptotagmin in CSF samples within sample set I (a, b) and sample set II (c, d). The four panels depict the measured levels of two tryptic peptides of synaptotagmin, 215–223 (VPYSELGGK) (a, c) and 238–245 (HDIIGEFK) (b, d). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease
Fig. 1 Targeted HR-PRM-MS analyses of synaptotagmin in human CSF. Individual values for the HR-PRM-MS measured peak area ratios ((endogenous peptide/labeled peptide standard) × 1000) of immunoprecipitated synaptotagmin in CSF samples within sample set I (a, b) and sample set II (c, d). The four panels depict the measured levels of two tryptic peptides of synaptotagmin, 215–223 (VPYSELGGK) (a, c) and 238–245 (HDIIGEFK) (b, d). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s diseaseCC BY · PubMed Central
Fig. 2 ROC curve analysis of synaptotagmin in human CSF. ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin 238–245 (turquoise and black) in CSF for differentiation of MCI due to Alzheimer’s disease (MCI-AD) from controls in sample set I and sample set II, respectively (a). ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin 238–245 (turquoise and black) in CSF for differentiation of dementia due to Alzheimer’s disease (AD) from controls in sample set I and sample set II, respectively (b). The area under the curve (95 % confidence interval) is shown in the included table (c). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease (Color figure online)
Fig. 2 ROC curve analysis of synaptotagmin in human CSF. ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin 238–245 (turquoise and black) in CSF for differentiation of MCI due to Alzheimer’s disease (MCI-AD) from controls in sample set I and sample set II, respectively (a). ROC curve analysis for synaptotagmin 215–223 (green and pink) and synaptotagmin 238–245 (turquoise and black) in CSF for differentiation of dementia due to Alzheimer’s disease (AD) from controls in sample set I and sample set II, respectively (b). The area under the curve (95 % confidence interval) is shown in the included table (c). AD dementia due to Alzheimer’s disease, MCI-AD mild cognitive impairment due to Alzheimer’s disease (Color figure online)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

Sorted by citations

Items 101–185 of 185

Related

See all

Metadata

Authors
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K.
Affiliations
  • Sahlgrenska University Hospital (SE)
  • Inserm (FR)
  • Lund University (SE)
Corresponding author
Öhrfelt, Annika
ORCID
Venue
Alzheimer's Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2016-10-03
Volume
8
Issue
1
Pages
41-41
ISSN
1758-9193 (ISSN-L)
DOI
10.1186/s13195-016-0208-8
PMC
PMC5048479
OpenAlex
W2529693680
Cited by
184
References
40
Citations by year
2026: 6 · 2025: 17 · 2024: 35 · 2023: 18 · 2022: 31 · 2021: 22 · 2020: 26 · 2019: 14 · 2018: 13 · 2017: 2
FWCI
7.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
  • Swedish Brain Power
  • Swedish research council
  • Swedish Alzheimer foundation
  • European research council
  • ALF
  • The Knut and Wallenberg foundation
  • Demensfonden
  • Eivind och Elsa K:son Sylvans stiftelse
  • the Wolfson foundation
  • Märtha och Gustaf Ågrens stiftelse
  • Gun och Bertil Stohnes Stiftelse
  • Stiftelsen gamla tjänarinnor
  • Magnus Bergvalls Stiftelse
  • Svenska Läkaresällskapet
  • Åhlén-stiftelsen
  • BMBF BIOMARK-APD
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
synaptotagmin-1, Alzheimer's disease, cerebrospinal fluid biomarkers, synaptic dysfunction, synaptic degeneration, mild cognitive impairment, dementia, cognitive decline, drug monitoring, neurodegeneration biomarkers, tau protein, neuroinflammation, neurofibrillary tangles, neurodegeneration
MeSH terms
Adult, Aged, Aged, 80 and over, Alzheimer Disease, Cognition Disorders, Dementia, Female, Humans, Male, Middle Aged, Peptide Fragments, Peptides, Psychiatric Status Rating Scales, ROC Curve, Mass Spectrometry, Amyloid beta-Peptides, tau Proteins, Immunoprecipitation, Synaptotagmin I

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review